Warner J O
Department of Child Health, University of Southampton, Southampton General Hospital.
BMJ. 1995 Sep 9;311(7006):663-6. doi: 10.1136/bmj.311.7006.663.
To review treatment prescribed to asthmatic children in Great Britain during the 12 months after publication of the first guidelines and to assess effectiveness of prophylactic treatment.
Review of prescribing information from January 1990 to June 1991 in a representative sample of general practices in Great Britain with a Compufile/AAH Meditel computer.
17,846 children with asthma aged 4-17 years.
Numbers of children prescribed different asthma treatments; estimated use of inhaled beta agonists in those receiving prophylactic treatment.
From January to December 1990, 9,362 (52.5%) children were prescribed preventive treatments. 16,211 (90.8%) children were prescribed bronchodilators of some kind. 3,055 (17.1%) were prescribed sodium cromoglycate, and the proportion decreased significantly during the study (from 19.5% (95% confidence interval 18.6% to 20.4%) to 17.2% (16.4% to 18.1%), P < 0.001, in children aged 4-11 years and from 14.9% (14.0% to 15.9%) to 11.3% (10.4% to 12.2%), P < 0.001, in those aged 12-17 during January-July 1991). 6,952 (39.0%) were prescribed inhaled steroids, and the proportion increased during the study (from 35.1% (34.0% to 36.2%) to 44.1% (43.0% to 45.2%), P < 0.001, in children aged 4-11 years and from 38.7% (37.4% to 40.0%) to 44.1% (42.7% to 45.5%), P < 0.001, in those aged 12-17 during January-July 1991). Only 1,358 of the 9,362 children (14.5%) received sufficient repeat prescriptions to suggest that they might be taking the prophylactic treatment regularly. Among these children short acting inhaled beta agonists were being used on average four to eight times a day.
These results are useful baseline data for audit of the impact of published clinical guidelines, particularly in terms of reducing the need for short acting inhaled beta agonists with prophylactic treatment.
回顾英国首次发布哮喘指南后的12个月内,针对哮喘儿童所开的治疗处方,并评估预防性治疗的效果。
使用Compufile/AAH Meditel计算机,对1990年1月至1991年6月英国具有代表性的全科医疗样本中的处方信息进行回顾。
17846名4至17岁的哮喘儿童。
接受不同哮喘治疗的儿童数量;接受预防性治疗的儿童中吸入型β受体激动剂的估计使用情况。
1990年1月至12月,9362名(52.5%)儿童接受了预防性治疗。16211名(90.8%)儿童使用了某种支气管扩张剂。3055名(17.1%)儿童使用了色甘酸钠,在研究期间该比例显著下降(4至11岁儿童中,从19.5%(95%置信区间18.6%至20.4%)降至17.2%(16.4%至18.1%),P<0.001;1991年1月至7月,12至17岁儿童中,从14.9%(14.0%至15.9%)降至11.3%(10.4%至12.2%),P<0.001)。6952名(39.0%)儿童使用了吸入性类固醇,在研究期间该比例上升(4至11岁儿童中,从35.1%(34.0%至36.2%)升至44.1%(43.0%至45.2%),P<0.001;1991年1月至7月,12至17岁儿童中,从38.7%(37.4%至40.0%)升至44.1%(42.7%至45.5%),P<0.001)。在9362名儿童中,只有1358名(14.5%)获得了足够的重复处方,表明他们可能在规律地接受预防性治疗。在这些儿童中,短效吸入型β受体激动剂平均每天使用4至8次。
这些结果是用于审核已发布临床指南影响的有用基线数据,特别是在通过预防性治疗减少短效吸入型β受体激动剂需求方面。